Understanding Parkinson’s Disease: Average Diagnosis Age and Key Factors

Parkinson’s disease is a progressive disorder of the nervous system that impacts movement. It develops gradually, often starting with subtle symptoms that may easily go unnoticed. While tremor is a hallmark sign, Parkinson’s can also manifest as stiffness, slowed movement (bradykinesia), and balance issues, increasing the risk of falls. In the initial stages, individuals might experience reduced facial expression, limited arm swing while walking, or changes in speech, such as softening or slurring. It’s important to understand that symptoms worsen over time, but effective treatments are available to manage them. Although there’s currently no cure for Parkinson’s disease, medications and, in some cases, surgical interventions can significantly help manage symptoms and improve quality of life.

Recognizing Parkinson’s Disease Symptoms

Parkinson’s disease affects individuals uniquely, and symptom presentation can vary widely. Early symptoms are often mild and may be so subtle that they are easily dismissed or overlooked. Typically, symptoms first appear on one side of the body before progressing to affect both sides, though they may remain more pronounced on the initially affected side. It’s also crucial to note that some Parkinson’s disease symptoms can overlap with other medical conditions, making accurate diagnosis essential.

Common symptoms of Parkinson’s disease include:

• Tremor: This is perhaps the most well-known symptom, characterized by rhythmic shaking, often beginning in the hands or fingers. It can also occur in the feet or jaw. A distinctive type of tremor is the “pill-rolling tremor,” where the thumb and forefinger rub together. Tremors may be most noticeable at rest or during times of stress and may lessen during activity or movement.

• Bradykinesia (Slowed Movement): Parkinson’s can significantly slow down movement, making everyday tasks more challenging and time-consuming. Simple actions like rising from a chair, showering, or getting dressed can become laborious. Facial expressions may become diminished, and blinking might become less frequent.

• Muscle Rigidity: Stiffness can occur in any part of the body, causing muscles to feel tense and painful. This rigidity can also lead to reduced and jerky arm movements.

• Postural Instability and Balance Problems: Parkinson’s can lead to a stooped posture and impaired balance, increasing the risk of falls.

• Loss of Automatic Movements: The ability to perform unconscious movements, like blinking, smiling, or swinging arms while walking, can be diminished.

• Speech Changes: Speech can be affected in various ways, including speaking softly (hypophonia), speaking rapidly, slurring words, or hesitating before speaking. Voice tone may also become monotonous and less expressive.

• Writing Difficulties (Micrographia): Writing can become challenging, with handwriting appearing cramped and small.

• Non-Motor Symptoms: Beyond movement-related issues, Parkinson’s can also cause a range of non-motor symptoms. These can include mental health challenges like depression and anxiety, constipation, sleep disturbances (such as acting out dreams or frequent urination at night), a reduced sense of smell, cognitive impairments affecting thinking and memory, and persistent fatigue.

It’s important to be aware of these diverse symptoms, as early recognition is key to seeking timely medical advice and management.

When to Seek Medical Advice

If you experience any of the symptoms associated with Parkinson’s disease, it’s crucial to consult a healthcare professional. Seeking medical evaluation is vital for accurate diagnosis and to rule out other conditions that may present with similar symptoms. Early diagnosis allows for timely intervention and management strategies to be implemented.

Image alt text: Doctor explaining Parkinson’s disease diagnosis to a patient, emphasizing the importance of early detection and management.

Unraveling the Causes of Parkinson’s Disease

In Parkinson’s disease, the root cause lies in the gradual breakdown or death of neurons in the brain. These neurons are nerve cells critical for transmitting information and controlling body functions, including movement. A significant impact of this neuronal loss is on dopamine production. Dopamine is a crucial chemical messenger in the brain, and its reduction leads to the characteristic movement problems associated with Parkinson’s.

The deficiency of dopamine disrupts normal brain activity, resulting in the motor symptoms of Parkinson’s. Furthermore, individuals with Parkinson’s also experience a reduction in norepinephrine, another chemical messenger vital for regulating various bodily functions such as blood pressure.

While the exact cause of Parkinson’s disease remains largely unknown, research suggests a combination of factors may be involved:

• Genetic Factors: Specific genetic mutations have been identified that are linked to Parkinson’s disease. However, these genetic links are relatively rare, except in cases where there is a strong family history of the disease.

• Environmental Influences: Exposure to certain environmental toxins or factors may elevate the risk of developing Parkinson’s later in life. Examples of such substances include MPTP, a contaminant found in illicit drugs, and certain pesticides, as well as well water consumption in some areas. However, it’s important to note that no single environmental factor has been definitively proven to be a direct cause of Parkinson’s.

Researchers are actively investigating various changes observed in the brains of individuals with Parkinson’s disease to understand the underlying mechanisms and contributing factors. Key areas of research include:

• Lewy Bodies Formation: A hallmark of Parkinson’s disease is the presence of Lewy bodies, which are abnormal clumps of proteins that develop in the brain. Scientists believe these Lewy bodies hold significant clues to understanding the disease’s origins and progression.

• Alpha-Synuclein Accumulation: Alpha-synuclein is a protein found within Lewy bodies. In Parkinson’s disease, this protein aggregates into clumps that cells cannot break down. The role of alpha-synuclein is a major focus of current Parkinson’s disease research, and its presence has been detected in the spinal fluid of individuals who later develop Parkinson’s.

• Mitochondrial Dysfunction: Mitochondria are the energy-producing units within cells. Dysfunction or damage to mitochondria can lead to cell injury. Such mitochondrial changes have been observed in the brains of people with Parkinson’s disease, suggesting a potential link to the disease process.

Image alt text: Illustration of a brain affected by Parkinson’s disease, highlighting the presence of Lewy bodies as protein clumps within brain cells.

Risk Factors Associated with Parkinson’s Disease

Several factors have been identified that can increase the risk of developing Parkinson’s disease. Understanding these risk factors can be helpful in assessing individual susceptibility and promoting proactive health measures.

• Age: Age is the most significant risk factor for Parkinson’s disease. The likelihood of developing Parkinson’s increases substantially with age. While Parkinson’s can occur earlier, the average Parkinson’s diagnosis age is around 70 years old. Onset before age 50 is considered young-onset Parkinson’s disease and is less common. However, it’s crucial to understand that while the average diagnosis age skews older, Parkinson’s is not exclusively a disease of the elderly.

• Genetic Predisposition: Having a close relative, such as a parent or sibling, with Parkinson’s disease increases an individual’s risk. The risk increases with the number of affected blood relatives. However, for most individuals, the overall risk remains relatively small even with familial history, unless there are multiple affected family members.

• Sex: Men are statistically more likely to develop Parkinson’s disease compared to women. The reasons for this gender disparity are still being investigated.

• Exposure to Toxins: Prolonged exposure to certain toxins, such as herbicides and pesticides, has been linked to a slightly increased risk of Parkinson’s disease. This highlights the potential role of environmental factors in disease development.

It’s important to remember that having one or more of these risk factors does not guarantee that a person will develop Parkinson’s disease. Risk factors indicate an increased susceptibility, but the disease’s development is complex and multifactorial.

Potential Complications of Parkinson’s Disease

Parkinson’s disease can lead to various complications, some of which are treatable. These complications can significantly impact quality of life and require comprehensive management.

• Cognitive Impairment: Parkinson’s disease can affect cognitive functions, including memory, language, and reasoning. In later stages, it can lead to dementia or other cognitive disorders. Medications for cognitive symptoms in Parkinson’s are available but often provide modest benefits.

• Emotional and Psychiatric Changes: Depression and anxiety are common in Parkinson’s disease, sometimes appearing early in the disease course. Irritability and worry are also frequently reported. These emotional and psychiatric challenges are treatable with medication and therapy.

• Swallowing and Chewing Difficulties (Dysphagia): In advanced Parkinson’s disease, muscle weakness can affect the mouth and throat, leading to difficulties with swallowing and chewing. This can result in malnutrition, choking, and drooling if saliva accumulates in the mouth.

• Sleep Disorders: Sleep problems are prevalent in Parkinson’s. Individuals may experience frequent awakenings, nightmares, and daytime sleepiness. REM sleep behavior disorder, characterized by acting out dreams, is another sleep-related symptom. Medications and therapies can help improve sleep quality.

Other potential complications include:

• Bladder Problems: Urinary urgency and other bladder dysfunctions can occur.
• Constipation: Difficulty with bowel movements is a common gastrointestinal issue.
• Blood Pressure Fluctuations: Orthostatic hypotension, a sudden drop in blood pressure upon standing, can cause dizziness, lightheadedness, and fainting.
• Loss of Smell (Anosmia): A reduced or absent sense of smell is often an early symptom of Parkinson’s.
• Fatigue: Persistent tiredness and lack of energy are common, particularly later in the day.
• Pain: Muscle and joint pain or cramps can occur.
• Sexual Dysfunction: Reduced sexual desire or performance may be experienced.

Management of Parkinson’s disease often involves addressing these complications to improve overall well-being.

Image alt text: An elderly man experiencing tremor in his hands, a common symptom of Parkinson’s disease that can affect daily activities.

Prevention Strategies for Parkinson’s Disease

As the precise cause of Parkinson’s disease is not yet fully understood, there are no definitive methods to prevent it. However, research suggests that certain lifestyle factors may offer some protective benefits.

• Regular Exercise: Aerobic exercise has been consistently linked to a lower risk of Parkinson’s disease. Engaging in regular physical activity is beneficial for overall health and may have a protective effect against Parkinson’s.

• Caffeine Consumption: Studies have indicated a possible association between consuming caffeinated beverages like coffee and green tea and a reduced Parkinson’s risk. However, further research is needed to confirm this link and understand the underlying mechanisms.

• Certain Medications: Some medications, such as ibuprofen and statins, have been suggested to be associated with a lower Parkinson’s risk in some studies. However, these findings are not conclusive, and these medications are prescribed for other primary reasons, not specifically for Parkinson’s prevention.

While these factors show promise, it’s crucial to emphasize that research is ongoing, and more studies are needed to establish definitive preventive measures for Parkinson’s disease. Adopting a healthy lifestyle, including regular exercise and a balanced diet, is generally recommended for overall health and well-being.

Conclusion

Parkinson’s disease is a complex neurodegenerative condition with a range of motor and non-motor symptoms. While the average Parkinson’s diagnosis age is around 70, it’s essential to recognize that the disease can affect individuals at younger ages as well. Early diagnosis and comprehensive management are crucial for improving the quality of life for those living with Parkinson’s. If you or someone you know experiences symptoms suggestive of Parkinson’s disease, seeking timely medical evaluation is paramount. Ongoing research continues to advance our understanding of Parkinson’s, paving the way for improved treatments and, potentially, preventive strategies in the future.

References:
[List of references as provided in the original article]

By Mayo Clinic Staff

Parkinson’s disease care at Mayo Clinic

Request an appointment

Diagnosis & treatment

Sept. 27, 2024

Print

Parkinson’s Disease Discussions

Colleen Young, Connect Director Living with Parkinson’s Disease – Meet others & come say hi 561 Replies Wed, Mar 05, 2025

chevron-right

Parkinson’s unresponsive episodes 80 Replies Wed, Feb 12, 2025

chevron-right

Is anyone using Rytary? 102 Replies Sat, Aug 24, 2024

chevron-right

See more discussions

1. Parkinson’s disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease#. Accessed April 3, 2024.
2. Kellerman RD. Parkinson’s disease. In: Conn’s Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed April 3, 2024.
3. Parkinson’s disease: Hope through research. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Parkinsons-Disease-Hope-Through-Research. Accessed April 3, 2024.
4. Loscalzo J, et al., eds. Parkinson’s disease. In: Harrison’s Principles of Internal Medicine. 21st ed. McGraw Hill; 2022. https://accessmedicine.mhmedical.com. Accessed April 4, 2024.
5. Stoker TB, et al. Parkinson’s disease: Pathogenesis and clinical aspects. htps://pubmed.ncbi.nlm.nih.gov/30702835/. Accessed April 4, 2024.
6. Ferri FF. Parkinson disease. In: Ferri’s Clinical Advisor 2022. Elsevier; 2022. https://www.clinicalkey.com. Accessed April 4, 2024.
7. Jankovic J, et al. Epidemiology, pathogenesis, and genetics of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 4, 2024.
8. Berg D, et al. Alpha-synuclein seed amplification and its uses in Parkinson’s disease. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00124-2.
9. Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using alpha-synuclein seed amplification: A cross-sectional study. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00109-6.
10. Post B, et al. Young onset Parkinson’s disease: A modern and tailored approach. Journal of Parkinson’s Disease. 2020; doi:10.3233/JPD-202135.
11. Ask Mayo Expert. Parkinson disease. Mayo Clinic; 2023.
12. Caproni S, et al. Diagnosis and differential diagnosis of Parkinson disease. Clinics in Geriatric Medicine. 2020; 10.1016/j.cger.2019.09.014.
13. Chou KL. Diagnosis and differential diagnosis of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 8, 2024.
14. Bower JH (expert opinion). Mayo Clinic. May 16, 2023.
15. Spindler MA, et al. Initial pharmacologic treatment of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 8, 2024.
16. Hauser RA, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson’s disease. Parkinsonism and Related Disorders. 2019; doi:10.1016/j.parkreldis.2019.03.026.
17. Mishima T, et al. Personalized medicine in Parkinson’s disease: New options for advanced treatments. Journal of Personalized Medicine. 2021; doi:10.3390/jpm11070650.
18. Jenner P, et al. Istradefylline — A first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics. 2021; doi:10.1080/14737175.2021.1880896.
19. Isaacson SH, et al. Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson’s disease psychosis. Journal of Parkinson’s Disease. 2020; doi:10.3233/JPD-202047.
20. Al-Shorafat DM, et al. β-blocker-induced tremor. Movement Disorders Clinical Practice. 2021; doi:10.1002/mdc3.13176.
21. Taghizadeh M, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurochemistry International. 2017; doi:10.1016/j.neuint.2017.03.014.
22. Parkinson’s disease: Fitness counts. Parkinson’s Foundation. http://www.parkinson.org/pd-library/books/fitness-counts. Accessed April 9, 2024.Green tea. Natural Medicines. https://naturalmedicines.therapeuticresearch.com. Accessed April 9, 2024.
23. Relaxation techniques for health. National Center for Complementary and Integrative Health. https://nccih.nih.gov/health/stress/relaxation.htm. Accessed April 9, 2024.
24. Haahr A, et al. ‘Striving for normality’ when coping with Parkinson’s disease in everyday life. A metasynthesis. International Journal of Nursing Studies. 2021; doi:10.1016/j.ijnurstu.2021.103923.
25. Mehanna R, et al. Age cutoff for early-onset Parkinson’s disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early-Onset Parkinson’s Disease. Movement Disorders Clinical Practice. 2022; doi:10.1002/mdc3.13523.
26. Nimmagadda R, Allscripts EPSi. Mayo Clinic. May 13, 2024.
27. Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: A cross-sectional study. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00109-6.
28. McKnight S, et al. Toxin-induced Parkinsonism. Neurologic Clinics. 2020; doi:10.1016/j.ncl.2020.08.003.